Avaan Therapeutics

Biotechnology ResearchUnited States11-50 Employees

Avaan accelerates new drug development leveraging global resources, primarily, emerging markets like India and China. Avaan's business model is to license and develop drug candidates chosen by its founding team of former Pfizer senior researchers and executives. Primary focus areas are CNS, Oncology and Diabetes. The Avaan team in US/Europe/Asia comes with successful global registration experiences on Norvasc, Zoloft, Viagra, Diflucan, Zithromax, and several others.

Management Team

Dilip Mehta, MD, PhD, Chairman
Rajnish Mishra, PhD, President & CEO
Al Kraska, PhD, Medical Director
Dave Dresback, PhD, SVP, Pharmaceutical Development
Sunita Rajadhyaksha, MD, Head of India Operations
Chirs Bonny, VP of Business Development
 
Strategic Advisory Board
Richard Fulmer, former VP Licensing and Development, Pfizer
David McGibney, MD, former SVP Clinical Development, Pfizer
Alex Giaquinto, PhD, former SVP Global Compliance, Schering Plough
Larry Stambaugh, former Founder & CEO, Maxim Pharmaceuticals
Robert Zerbe, MD, CEO of Quatrx Pharmaceuticals formerly SVP Clinical Research-Parke Davis, VP-Eli Lilly.

Sign up for free to view info

Email Format Employee directory